Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Controlled comparison with intracoronary streptokinase  by Anderson, Jeffrey L. et al.
Multicenter Keperfusion Trial of ~ntr~ve~~~s Anisoy 
Streptokinase Activator Complex (APSAC) in Acute 
Infarction: Controlled Comparison With Intracoronary Stre 
JEFFREY L. ANDERSON, MD, FACC. RDBERT 1.. RMHRARD, MD, FACC,* 
ROSEMARY A. HACKWORTHY. MB. BS. SHERMAN G SORENSEN, MD, FACC. 
PATRICIA G. FITZPATRICK, MD, FACC,* CHARLES F DAHL. MD. FACC. 
ARTHUR 0. HAGAN. MD, FACC. KEVIN F. EROWNE. MD. 
GARY P. SYMKOVIAK, MD, FACC. RONALD L. MENLOVE, P,,D, 
WILLIAM H. BARRY, MD, FACC. HARRY W. ECKERSON. PHD. 
VICTOR J. MARDER. MD” FOR THE APSAC Mu~rlrmren INV~STIGATORS~ 
The central role of coronary thrombosis as an initiating 
mechanism ofacute myocardial infarction has now been well 
documented and is widely accepted (1.2). The feasibility of 
coronary thrombolysis in acute myocardial infarction with 
the use of various plasminogen activator regimens, most 
commonly intracoronary or intravenous streptokinase, has 
been well demonstrated III recent years (WI and extensively 
reviewed (8-12). Studies in which thrombolytic therapy *as 
initiated early rdier symptom onset (52 to 4 b) have shown 
reductions in morbidity and improved cardiac functional 
outcome Wl9j. whereas later application has generally not 
shown improvement (20-24). Most importantly. the benefi- 
cial potential of thrombolylic therapy on early postmyocar- 
dial infarction mortality has now been demonstrxed (X-30). 
of more ideal thro~bolytic agents and mechanical me;hods. 
such es coronary balloon angioplasty (31). to provide more 
elT.ective arly reperfusion. Streptokinase. despite causing 
extensive systemic fibrinogenolysis. is less effective when 
given by the intravenous than by the intracoronary route, 
especially when therapy is given relatively late (>4 h) after 
symotom onset (7.21). Earlv rewclusion after thrombolvtic 
Current investinative interest focuses on the development 
bolytic regimens can be well defined only by angiographi- 
ally controlled trials of adequate size, and can he ade- 
quately compared with previously accepted standard 
regimens only by randomized. controlled studies. Therefore, 
the present trial was designed to evaluate the etfects of 
intravenous lherapy with APSAC on angiographically dem- 
onstrated coronary artery occlusion in acute myocardial 
infarction and to compare this with that of art approved 
regimen oiintracomnary thrombolyric therapy in a random- 
ized, multicenter study in the United States. 
Methods 
APSAC in patients &h acot, myocardial infarction. and 2) 
The primary aims of the present trial were I) to evaluate 
the reperfusion et%r+cv. safetv and tolerance of intravenous 
to compare this result with that for the siandard thmmholy- 
tic regimen of intracoronary streptokinase. given as rip 
proved by the United States Food and Drug Administration 
(FDA). The study was designed to evaluate and compare 
two methods of applying thrombolytic therapy rather than 
the wo apents as such. 
therapy with or without combined coronary angioplasty is a
problem no1 only with streptokinase (9,32) but also with the 
patent fibrin-specific thrombolytic agent, tissue plasminogen 
activator (t-PA1 (7.33.34). Because of its short half-life and 
the high incidence ofreocclusion. t-PA is administered as a 
prolonged intravenous infusion over 3 to 8 h. The rate of 
intravenous rtreptokinase administmtion for acute myocar- 
dial infarerion most also be prolonged to 30 to MI min to 
avoid significant hypotension: 
A,dsoylared pfusminogcn streptokinase acrivalor com- 
plex (APSAC) was synthesized to improve on the kinetics of 
streprokinase-plslminogen a d confer properties well suited 
to rapid. long-lasting intravenous thrombolytic herapy (351. 
APSAC is chemically protected at its active site on the 
plasminogen molecule by an acyl (anisoyl) group so that, on 
injection, nonspecific activation and fihrinogeoolysis are 
avoided, but the ability to find and bind to fibrin is retained 
05.36). APSAC is activated semiselectively at the site of 
dot by hydrolysis. but causes systemic fibrinogenolyais 
when riven to patients in doses of al0 mg (IO U) (36.37). 
The libnnolytic activity of APSAC is cleared slowly: the 
plasma half-life averaees about 120 min cornoared with I5 to 
ZO min for streptok&se (36). Enperiment~l studies have 
shown superior clot hindinp, and Iysis with APSAC and less 
hypotension with bolos in&ion-than are associated with 
streptokinase-plasmin, probably because of more gradual 
generation of plasmin and bradykinin (36). These potential 
advantages led to the clinical development of APSAC. 
Early trials of APSAC administered intravenously to 
patients with acole myocardial infarction showed it to he 
well totemted and cflective in a high proportion of patients 
(3743). However. the reperfusion cficacy of new thmm- 
Patie~seieftion. The study was considered for patients 
<76 years of age who had I) symptoms of acute ischemia 
(chest pain) 2% min duration. and 2) electrwudiographic 
(ECG) ST segment elevation R0.I mV in one or more limb 
leads or ~0.2 mV in one or more precordial WI leads 
suggestive of ischemic injury, whcse symptoms and signs 
were not relieved by sublingual nitroglycehn and in wh& 
thromholytic therapy could be given within 6 h of symptoro 
otwt. After writien consent was obtained, angiographic 
documentation of coronarv arterv wclusion (TIMI trade 0 
or I flow 171) was required ior stoiy entry. R&domiz;ion to 
APSAC or streptokinase was then performed. 
Excltaaion rrikril: inc!:;ded cnrdiogenic shock (systolic 
pressure 580 mm Hg): a hemonhagic diathesis; fuli dose 
anticoagulant therapy: recent history of active peptic ulcer- 
ation: history of cerebmvascular accident: cardiopulmonary 
resuscitation or other significant trauma related to the acute 
myocardial infarction event; severe hypertension (systolic 
pressure 2208 mm Hg or diastolic pressure >I20 mm Hg); 
surgery within IO days: coronary artery bypass wrgery or 
percotaneow translorninal coronary angioplasty within I 
month: streptokinase therapy within 6 months: pregnancy. 
lactalion or childbearing potential sod conditions of pros- 
thetic valves, dilated cardiomyopathy or ventricular aneu- 
rysm with mural thrombos. 
The srrtdy wns Csigncd with a recrrdrment goal of 200 to 
250 evnhtable parienrr. with an interim aoalyrir afterapprox- 
imately IL% eotered patients and a final analysis on study 
completion. This study size allows detection of a difference 
in reperfusion rates between streptokinase and APSAC of IS 
to 20 percentage points, which would be of clinical rek- 
vance. with a power of 0.8. Between February 198s and 
January 1987,329 patients with acute myocardial infarctkm is partial perfusion: contrast medium passes across the 
were screened for the study and signed consent. and 258 obstructmn and opacities the distal coronnry bed. but lhe 
were judged to show qualifying coronary occlusion (Row rate of entry into and clearance from the distal bed is 
grade 0 or 1) at cardiac atheterization and were randomized delayed. Grade 3 Row is complete perfusion: anterograde 
to a treatment arm at the time of angiography. Of these, 240 Row occurs at a normal rate of filling and clearance in the 
patients fulfilling all an&graphic and ECG entry criteria and distal bed. Repelfusion was defined as the advancement of 
actually raeiving the assigned study drug regimen in the 23 
participating medical centers (see Appendix) form the basis 
grade 0 or I to grade 2 or 3 flow. 
Parients were monirored in rhe bboruiorv for 90 min. and 
for the study analysis. reperfusion shl*u~ was assessed al each.i5 min &val 
In general, patients signing consent but not randomized ungiow~m. Reperfusion end points designated to be of 
did not have coronary occlusion at angiography. The I8 
patients who were randomized but excluded from formal 
interest were I) reperfusion at-any time within the 90 min 
analysis because of major protocol violations were equal!y 
(“anytime reperfusian”), and 2) the “clinical comparison 
end pain:” Istatus at 90 min for intravenous and 60 mitt for 
classilied betweett~oups.(nine APSAC, nine streptokinase). 
Exclusion resulted f-an failure to meet ECG criteria for 
inlracoronary therapy). The timing of the clinical compari- 
acute mycardial ink-tion (seven APSAC, four streproki- 
son end point (or prolocal reperfusion) was prospeaweiy 
defined by the investigators cm the basis of conventions of 
nase patients), failure to &w angiouaphic occbsion on previous trials for intracoronary (26.28) and intravenous 0, 
review (on; and three pat~et.tr, espectively) or receipt of therapies, FDA labeling information (for streptokinase) and 
incorrect study medication (one and tw patients. respec- clinical practice for the two routes of administration. These 
lively). In each assigned group, three of eight excluded limes are wpported by phasmacokinelic observations that 
patients who had an&graphic films showed perfusion at 90 indicate intracoromw strentokiwase cause rewfusion at a 
min. No deaths occurred among the randomized but ex- mean of about 30 mi;l (9,i3,26) and intrwenbus streptoki- 
cluded patients. Study conclusions are not affected by ex- nase P-7.9) at abwt 45 min. Reperfusian was thus assessed 
cluded patients. at twice the exwcted rewrfusion times for each route. 
%dy plan. The study was designed to evaluate and 
compare two thrambolytic repetfusion approaches: an ex- 
peritttental intravenous regimen and an approved standard 
intracoronary regimen. Randomization was performed for 
qualifying patients after coronary angiography by opening a 
blinded, consecutively numbered box containing a vial of 
one or the other drug. Therapy was thereafter unhlinded. 
APSAC (30 U) was reconstituted to5 ml with sterile wateror 
saline solution and administered intravenously over 2 to 4 
mitt. Streptokinase (ZSO,wO U/vial) was reconstituted and 
diluted to a concentration of 1,ooO U/ml with dextrose or 
saline solution and given by infusion through the coronary 
catheter into the ostium of the infarct-related artery. Ln 
keeping with the FDA-approved labeling infomntion. intra- 
coronary streptokinase was initiated with a 20.0&l U bolus 
administered over I to 2 min and followed by a continuous 
infusion of 2,tXM Ulmin for 60 min. After c~mntencetnent of
fibrinolytic therapy, repeat coronary arteriography was per- 
formed at 15 min intervals for 90 min to assess coronary 
artery patency. After each interval arteriogram. a reloading 
holus dose of lO.ooO U intracoronary streptokinane was 
given. The total dose of streptokinase actually administered 
averaged 156.wO U for the slreptokinase study group. 
Supplrmen&v de& and interventions. Ethical con- 
siderations uggested additional interventions be allowed at 
the physician’s discretion (e.g., supplemental inrmcoronary 
streptokinase. guide wire manipulation, coronary balloon 
angioplacty. coronary anery bypass surgery) after determi- 
nation of drug failure at 60 min in the intracoronary group 
and 90 min in the intravenous grwp. Patients exhibiting 
successful reperfusion were encouraged to be followed-up 
with usual medical therapy alone for 24 h. at which time 
repeat coronary angiography was performed for the deter- 
mination of continued coronary patency or reocclusion. 
However, other interventions were allowed in successfully 
trcatcd patients alter the 90 min observation period if they 
were deemed medically indicated (e.g., for grade 2 flow. 
threatened reocclusion or ongoing or recurrent imhemia). 
Reperfusion rates by lime from sympmm onser to rhrom- 
bolyric lhernpy were analyzed in two subgroups of clinical 
interest (54 hand >4 h). defined prospectively at the time of 
an early interim analysis. Analysis was also performed on 
entry times dicb-atomized at the znedian. 
Final proload determinadons of nn.&ropldc quol~ca- 
lion and rheropeutic reperfurion were made by blinded 
readings of films by two independent observers at the central 
tine IaLwratory. Whenever the two readings did not concur 
in the a~sesanent ofstudy qualification. reperfusion success. 
time to reprfusion or presence of reocclusian, final patient 
status was determined by considering the reading of a third 
independent, blinded &server. 
Hepwin. Heparin was given in a dose of 5,wO U at the 
start of catheterization. After streptokinase. a heparin main- 
Reperfusion Lrermination. The extent of coronary ar- 
tery perfusion was gmded on a scale of 0 to 3 according to 
the TIM1 criteria (7). Grade 0 represents no anterograde Row 
beyond the point of occlusion. Grade I Row is clot pene!ra- 
lion of dye with minimal distal perfusion: contrast materihl 
passes beyond the area of obstruction but “hangs up.’ and 
fails to opacify the entire distal coronary bed. Grade 2 Row 
tenance infusion (l,Mkl U/h1 was commenced empirically at 
a30 ntin after infusion or, alternatively, at the laboratory- 
guided estimated time of decline of the thmmbin time or 
partial thromboplastin time to twice normal levels @wrdly 
at 2 to 6 h). After inFusion of APSAC. heaarin administration 
was commenced empirically at 4 to 8’ h. the lime when 
fibrinogen levels begin to rise from their nadir (371, or as 
guided by rapid blood testing. The mean time at contmence- 
ment al heparin therapy was 4.1 h in the streptokinase and 
6.1 h in the APSAC group (p L 0.03). 
To rtwluore conrinurd posrtlrrombolysis coronrlly ortety 
patency and rrocclusion. angiography was repeated after 24 
h in all patients with reperfusion who were not undergoing 
additional procedures. Only procedures deemed clinically 
necessary on an emergent basis were allowed within the 1st 
day. 
Clinical and I&roruton observntioos. Vital sians, adverse 
reactions to drug and clhdcal conditions suggesiive of coro- 
nary reocclusion. heart failure, bleeding and other compli- 
cations associated with acute myocardial infarction or ther- 
apy were closely monitored for 24 h after dosing and then 
followed up until horpitel discharge. 
A I2 lend ECG wm recorded in all pa&-nls b&m 
treornwrr. Electrocardiograms were analyzed by a single 
observer who did not know patient characteristics and 
outcome. The rum of ST segtnent elevation in all leads 
except aVR was measured in millivolts above the isoelectric 
baseline. 
Blood was cvllrcwdfir me~sw~ment of serum crenrinr 
kinuse fCKJ and irs MS isoenzyme fMB CKJ before treef- 
mm, and at W mitt. 4, 8, 12. 18 and 24 h after treatment. 
Serum lactate dehydrogenase and its isoenzyme 1 (LDH-I) 
were measured before lrealment and at 90 mitt, d. 24, 36,4S 
and 72 h aiter treatmstu. Enzyme assay determmations were 
performed by the individual hospital laboratories and values 
compared with their normal control range. The peak level of 
enzyme and isoenzyme values was estimated for each pa- 
tient. Hematologic detemdnations were made before treat- 
ment and at YQ min and 24 h after the start of treatment, and 
included hemoglobin, hematocrit. partial thromboplastin 
time. prothrombin time, thrombin time, plasma fibrinogen 
fthmmbin-clortable protein) (441, euglobulin lysis time (45). 
caseinolytic measures (461. plasmino9eo, free plasmin and 
alpha-2.plasmin inhibitor and serum fibrinogen desmdation 
products. 
Statistical antdysls. Resulls for continuous variables arc 
presented as mean f SD or, where indicated, t SE. 
Student’s unpaired I test was used to assess differences in 
continuous variables. including entry characteristics and 
enzymatic variables. Categorical variables. including initial 
~uronary flow grade. time from symptoms to initial treat- 
ment (dichotomized at 4 h and at the median [to maximize 
cell balance]l. infarct-related artery. drug and repetfusion 
s!atus were evaluated for importance by a stepdown log 
Table 1. Entrv Characteristics of 240 patients 
linear regression model. The influence of these variables on 
repetfusion stalus was subsequently verified using Pearson’s 
chi-square test and logistic regression analysis. A probability 
SO.05 was taken as significant. 
Results 
Entry characterlstirs aI study grow (Table 1). A total of 
240 qualifying patients, entered. randomized and receiving 
drug therapy: form the basis of this report. Eighteen other 
patients were randomized but are not included in the analv- 
sis beeause of major protocol violations at entry (see Meth- 
ods). Of qualifying patients. 123 were randomized to intra- 
venmu APSAC and II7 to intrac~ronary streptokinase 
thenpy. Entry characteristics did not differ between groupa. 
Enlered patienls were 57 i 9 years in age, and the majority 
(83%) were men. Time from onset of symptoms lchest pain) 
to therapy averuged 204 + 60 min (range 23 to 359). 
Substantially more infarct-related arteries showed initial 
grade 0 than grade 1 flow in both croum. In both treafutent 
groups. the infarct-related aflerywas~tnost commonly the 
right coronary artery. followed by the left anterior descend- 
ing and left circumflex coronary arteries. 
A~@,tc reperfmi~,, results (Table I). lntravcnous 
APSAC achieved reperfusion a, any time within 90 ,nin in 
55% (67 of 122) of valuable padents. The time io initial 
reperfusion after APSAC averaged 43 + 23 min. Reperfusion 
prsisted at the end ofthe 90 min observation period (clinical 
comparison end point) in 51% (59 of l IS). 
“Anytime reperfusion” was observed in the comr01 
intracoronary streptokinase group in 64% (73 of 114) of 
waluable patients (p 5 0.16 verws APSAC) and was present 
in 643% (67 of 1111 of evaluable oatienls a, the end of the M) 
min infusion (clinical comparison end point) (p r 0.18 verw 
APSAC). The time to initial reperfusion was shorter after 
initiation Of intracoronary therapy, averaging 31 Z? 17 min (p 
B O.ora3). 
A parallel comparison of ne, repperfrrsion rates for Ihe matzo 
~reamwnt regimens is show% in Fibwe /for each 15 min rime 
interval. As anticipated. a relative plateau in the reperfusion 
versus time-from-therapy curve occurred by 45 to M) min For 
intracomnary but not until 90 min for intnvenous therapy. 
.Lne e&pendency WE &wed ~o;‘intravenbus iherapy: 
APSAC was successful in Ml% (47 of 79) of oatients treated 
in 54 h. compared with only 33% (I2 of 36) ireated after 4 h 
Ip 5 O.Oll (Fig. 2). In conwart. intracoronary therapy 
(strepmkinase) was simitarly effeclive in those treated in r4 
h (60% IS0 of 83,) and after 4 h (61% I17 of 281) tp r 0.97). 
Comparisons between treatment xrou~)s by time ,o theraw 
showed similarresultsfor treatment iis4 h but signif&& 
different results by treatment route after 4 h Q 5 0.031. 
Identical conclusi&s were reached if the men&n time to 
treatment 1205 min) was used to dichotomize the data. 
l/w freqorncy of reperfusion was highly deplrpmmlenr on 
inirinl coronary flow erode for both rherooies. In Datients 
with initial @-a& t R&. rep&union oceu&d in 78E/b (45 of 
58) of patients compared with 48% (81 of 168) with grade 0 
flow lp 5 O.oWI). Repafusion results by initial angiographic 
flow grade were similar for APSAC and streptokinase (Fig. 
3): for patienls wi,P gnde I Row. 78% (21 of 27) after 
APSAC and 77% (2.4 of 3,) afreer smptokinase: for patients 
with grade 0 Row. 43% (38 of 88) after APSAC and 54% (43 
of 801 after streptokinase (p 5 0.18). Grade I Row as 
present in 3G’% (48 of 162) of patients evaluable for rep&,- 
T&k 3. Changes in Vita! Signs After Thmmbulylic Therapy in 
240 Padents 
Fiire 4. P~ctoccl cornnary reperfuaicn by infarct-related artery 
and treatment group. CX = le” nrc”mRex coronary ancry: LAD = 
Eefl anterior dewending coranary artery: R : dght cumnary artery. 
Other abbreviations a in Figure 1. 
tbc mosf poaer.ulprrdieror of reper~itsbxz for both groups of 
parienrs (APSAC, p 5 O.MN39; slrcptokinasc, p 5 0.04). and 
median time to treatment was a powerful predictor of spy and within 24 h were frequenr, being performed in 3% 
repcrfusion far APSAC (p s 0.0014) but not tar strcptoki- of patienls receiving APSAC and 58% of those receiving 
case-treated patients. Findings were similar when time was streptokinasc. As expected, such interventions wcrc more 
dichotomized at 4 h. Stepwise logistic regression analysis frequently used in pnticnts not achieving reperfusion (63%) 
was done using time fmm symptoms to treatment and initial than in those achieving successful rep&&n (34%. p 5 
Row grade. Time to treatment was used in the first step 0.031). These interventions included additional intrawro- 
because if would be available lo the clinician before intrwe- nan streptokinase fonlv) in 19 ~liemr. eoronarv wide wire 
ncus thrombolytic therapy. Initial Row grade was introduced 
as the second step to determine iffindings at initial eorcnaty 
angiography would further assist in the prediction of rcpcr- 
fusion. Time alone was a significant predictor of rcperfusion 
status for patients given APSAC hut not for those given 
slreptokinase. When initial flow grade was added to the 
mode!, the ability to predict repcrfttsion was significantly 
improved in the APSAC group (p s 0X03) and Lecamc 
significant in the strcptokinasc group (P 9 0.019). The smnc 
findings were obtained when time &shichotomized by 4 h. 
Rep&&on by infsrct.~lated artery (Fir?. 8. Rcpcrfu- 
sion results did not d&r significantly in ihe site if the 
infarct-related artery. APSAC achieved successful reperfu- 
sion in 56% (23 of 41) patients with left anterior descending 
coronary artery ccclusion and 51% (36 of 71) of those with 
left circumflex or right corcnw artery occlusion !D c 0.59). 
Success rates for streptckinax by. infarct-related a&y 
were 64% (23 of 36) and 59% (44 of 75). rcscectivelv ID c . 
0.60). 
Rmcclusicns and theqeutic Intcrvenlicns within 24 h. 
Rmcclusion occurred within the 90 min laboratory obscrvb 
tion period in 6 (9%) of the 67 pcticms in the APSAC group 
with initial Gmytime”) reperfusion and ! I (IS%) of the 73 
paticnls with initial reperfusion in the strcptokinase ~muc (p 
ma&d&on (with.or ‘tithout- added strep&&&) in 14, 
coronary angioplasty in 73 and coronary byprw surgery in 
IO. 
Rates of coronary patency and reccclusion between 90 
min and 24 h after thrombolytic therapy were assessed 
angicgraphically in patients not undergoing further intcrven- 
lions. Interval reocclusion at 24 h was observed in only 3 of 
40 patients receiving APSAC and I of 37 cvaktabk patients 
receiving strcplokinasc. 
Hemodynomic, Laboratory and 
Safety Evaluations 
Changes in vila! signs (Table 3). The hemodynamic tolcr- 
ante of rapid intravenous injections of APSAC was generally 
good. However, an initial decline in blood prc~rurc was 
observed cfter administration of APSAC; the decrease was 
usually mild to moderate, although greater than that arscci- 
ated with the slowly administered, small doses of intracoro- 
nary slrc~tokinase. Ducing APSAC injections (2 to 4 min). 
mean blood prcssurc decreased by a median of IO mm Hg 
(mean 14), compared with a median decrease after strepto- 
kinasc of 5 mm Hg (mean 4) (p 5 0.002, APSAC versus 
strcotokinase. Mann-Whitnev test). At the trextment end 
5 0.50). 
Additional inlewenrions $hort/y after drombo$ric (her- 
p&t of 90 mis, ills cilar.gbfrcm’base!in in mean bleed 
pressure averaged -I I f 18 mm Hg for the APSAC and -8 
+ 17 mm Hg for the streptokinase group (p 5 0.20 for 
comparison). These late changes may largely represent the 
oatural history of acute myocardial inhrction and the vase- 
dilating effects ofradio eotttrw medium. A small increase in 
pulse rote, averaging 6 i I8 beatrimin in patients given 
APSAC (p 5 0.002) and 5 + I5 beatsimin in those given 
strebakinase to d 0.W~ was observed 2 to 4 min atIer 
co&neocemen~ of therapy (p 5 0.95 for intergroup compar- 
ison). At 90 mitt, the pulse rate change was +6 + I8 
(compared with pretrea;ment) for APSAC and t8 + 19 
beatslmin for streptokinase therapy (p 5 0.44 for intergroup 
comparison). 
Chaoges in Mood coagolatioo variables with therqy (Table 
4). APSAC in the administered ose of 30 U, equivalent o 
approximately I million units of streptokinase, Fared sig- 
nificant and prolonged librioogenolysis. Of the 240 patients, 
209 b.ai Sets of blood samples walttable for fibrinalytic 
variables at the 90 mitt data point and 190 at 24 h. The 30 U 
dose of APSAC had a significantly greater e&t on plasma 
alpha-2 antiptesmin. ptasmioogen ad fibrinogen concemra- 
tions than did the 156,OMt U mean dose of rtreptokinase. 
Mean plasma fihrinoaen levels fell to 32% of oretreatment 
values at 90 min after APSAC compared wiih 64% after 
streptokinase (p L 0.001); levels returned to 79 and 88% of 
baseline, respectively, by 24 h. Similarly, plasminogcn and 
alpha-2 antiplamin fell to 22 and 18%. respectively, at 90 
mio efter APSAC, about half the levels observed after 
intrecomnery streptokinase. Levels improved toward base- 
line and showed &taller intergroup diierences by 24 h. 
Bkedii~ compliatii and other adverse reprtkms (Table 
5). Adverse experiences after APSAC were those xpected 
for equivalent doses of streptokinase. Objective measores of 
bleeding did not differ significantly. A fall in hematocrit of 
at0 percentage points within 24 h of treatment was noted in 
21 of I I3 patients treated with APSAC and IS of I03 patients 
given streptokinaae (p 5 0.50). No intracranial hemorrhages 
occurred, and no deaths caused by hemorrhage were ob- 
served in either group. Transfusions unrelated to coronary 
bypass surgery were given to ?I patients given APSAC and 
12 given streptokinase (p L 0.25). 
more frequent for mtients E&en APSAC (64 versus 45%) but 
were more often &ded &severe for those given streptoki- 
nase I26 versus 15%). Bleeding was reponed in 36 patients 
(29%) Siven APSAC and I6 (14%) of those given rtreptoki- 
nose Ip 5 0.005). In the APSAC group. bleeding was 
locabzed I the site afcathctcr insertion Ipin, in 23 patients 
aad occurred elsewhere in 17. In the streptokinase group, 
bleeding was reported at the catheter insenion site in I I 
patients and elsewhere in 7 (p 5 0.05 for intergroup cornpar- 
isons). 
Olber adverse exoeriences were tvpical of those expected 
for acute myocardial infarction and.for therapy with-strep- 
tokinase-related agents and occurred about equally in both 
groups. Possible allergic reactions (mild1 were noted in I I 
t&nts eiven APSAC (fever in 4. chills in I. fever and chills 
in I. fev&and rigors in I, Rushing in I, facial flushing. edema 
and chills in I. flushing and chest pressure in I and eryihema 
in I) and in 9 patients given streptokinase (fever in 5. chills 
in 2, fever and rigors in I, wheezing and dyspnea in I) 
(p=NSl. One patient in the streptokinase group suffered 
cerebral vascular accidents which were nonhemorrhagic (by 
computed tomography) and occurred later in his course, 
after coronary bypass surgery (at 2 day, IS day). 
Early mortality. In-hospital mortality rates were rela- 
lively Iw in both treatment groups (APSAC = 5, streptoki- 
ease = 9, p 5 0.3). Three deaths occurred during day I in the 
APSAC and two deaths in the streptokinase group (all due to 
cardiogenic shock). Nine deathsoccurred afterdav I: two in 
the AFSAC group (days 2 and SO) and seven in th-e strepto- 
kinase ,?,o”p (days 2.3.5. 6. 9. IS and 191. No deaths wore 
believed tobe treatment related. 
Rnqmstic compxlsoos (Table 61. Evolution of the serum 
cardiac enzyme was similar in both groups. 
The results of this multicenter. angiogmphically coo- 
trolled rhrombolysis study in acute myocardial infarction 
suggest that therapy with intravenous APSAC achieves a 
reperiusion rate ofabout 6i3% when the agent is administered 
within 4 h of symptom onset. The tale of reperfusion is 
dependent on time and declines ubstantially when therapy 
is delayed until after 4 h. APSAC, like streptokinase, is more 
effective when even minimal anterograde Row (grade I) is 
initially present han in the face of total occlusion (78 versus 
43% reperfusionl. 
Intravenous APSAC versudi intracorouary streptakinase. 
The present study is among the largest baseline, angiogra 
phically conlrolkd trials of au intravenous thrombolytic 
agent (6.7.47.48): it is also one of the largest trials of 
inlracomnary streptokinase (26,281 and one of thr few 
studies to determine repetfusion in a stringent, graded fasb- 
ion (7.47,481. The comparison of these two therapies hows 
intravenous APSAC to be similarly efficacious when given 
early (within 4 h), but less &icacious thereafter. Fortu- 
nately. patients presenting early after symptom onSet form 
the group that stands to benefit most from coronary roper- 
fusion (IO.&19.301. intravenous therapy also rewires an 
average of I2 min more than intracoronary therapy to 
achieve reperfusion, but this is more than compensated for 
in the clinical setting by enabling therapy without initial 
catheterization (49). The intravenous regimen caused greater 
fibrinolvsis. hvootension and minor bleedine than did low 
dose intracoronary therapy, but the drug w&easily admin- 
istered, clinically well tolerated and was associated with low 
rate8 of significant morbidity and mortality. 
Coronary repwfuslon rates with APSAC therapy. Reper- 
fusion rates observed for intravenous APSAC are favorable 
when compared with those for intravenous :wptokinae in 
studies using a similar strict determination of moerfusion 
end points (7.47.481. Hipher reoetfusion rates for iotrave- 
nou; streptokinase ‘prev~usly r&ted may in part r&cl 
less strict angiogmphic definitions of reperfusioa (e.g., pa- 
tency rates with no baseline confirmation of occlusion or no 
angiographic grading ofoutcome) (5,11,50.511. Ourdetemd- 
nation of reperfusion followed the stringent method of the 
recent Thrombolysis in Myocwdial Infarction study VIM11 
(7). The reperfusion rate of 51% at Xl min for APSAC is 
greater than the 31% (37 of 119) rate reported in the TIM1 
study for I.5 million U of intravenous treptokinase (7). The 
repafusion mte for APSAC administered within 4 h @I%1 
also compares favorably with that observed in the TIM1 
sludy for t-PA (62%, 70 of 113). and is greater than that of 
intravenous treptokinase given within 4 h (44%). Mean time 
lo reperfusion with APSA? (43 minl in this study compares 
favorably with that reported for intravenous therapy with 
streptokinase (55 min) and t-PA (49 min) (71. 
The rime dependence for intravenous thrombolyric lher 
rrpy with areprokinase-like ogenrs may help to explain the 
higher success (patency1 rates reported in studies in which 
therapy was administered within 2 h of the onset of symp- 
toms of acute myocardial infarction (IS). Time dependency 
might relate lo changes in clot susceptibility to srreptokinax! 
lysis with aging as well as to a changing spectrum of 
occlusion grades. Allhowh treatment in our studv was given 
r&lively &ly, pretreat&u catheterization t&sit&s a 
d&v of about 90 min (491, which will be avoided when 
APiAC is administered in the usual clinical setting. 
Comparison with iotrammnary streutokinrre. The sekc- 
lion of intracoronary streptokinase as Ihe conlml arm and its 
results (37.43). Dosing experience in these trials suggested 
dose and duration of administration deserve comment. Dur- 
30 U 00 mg) ro provide optimal pxeocy or rep&Go rates. 
ing initial new drug development. bderal (FDA) policy 
In on early. anglographically controlled United States study, 
Marder et al. (3’1) achieved repezfusian with APSAC in m 
requires controlled comparisons with placebo or with oo of a small paticnt series treated with a dose of 30 U but in 
approved standard therapy. Comparison wth placebo was only Zt% treated wi?h 5 U. Kasoer et al. 1411 observed earlv 
considered unethical t the time of this study,and inwave. patency (at 1 hl in 32 (64%)‘of 50 pa&s given 30 6 
nous thmmbolytic therapies (streptokinase. t-PA) were not APSAC: subsewe.:t reoerfusion lat 75 mini occurred in an 
appruved until November 1987. Thus, despite its appeal as a additional IO patients fdr an 84% eventual s&ess rate. In a 
control anu. intravenous treptokinase was not acceptable. 
Comparison with intracoronary streptokinase is also of 
small. angiographically conwdled comparison with placebo 
interest, however, becailsc it is recognized as providing near 
(42). APSAC achieved reperfusion in 56% (9 of 16) compared 
with olacebo (9%. I of II) (v 5 0.05) (421. A wetiminarv 
optimal repafusion rates in throo&ysi&ceptibie pa- 
tients (I I) sad coo serve as an important internal control for 
. r , 
report (52) from an aogiagraphicolly controlled Dutch com- 
parative study with a design similar to that of our stodv 
assessing the degree to which an intravenous regimen suggests a similar result. P&us were treated at a mean df 
matches or falls short of this standard of near optimal 2.3 h and 65% achieved repmfusion after APSAC. cornpam 
lhmmbolysis. (In ow study, APSAC matches this rote if 
given within 4 h. but gives lower reperfusion rows after 4 h.1 
hle with the 60% result for treatment within 4 h io the present 
study; intrhcomnary rtreptokinasz achieved repifusion in 
Because intravenous streptokinase has been shown to be 68%. Of even greate: interest is the potential for substantial 
aenerallv less etTeective than intracoronarv streotokinase reductions in momlitv with APSAC (4% 
(21). a favorable indirect comparison of the ~esultsbbserved Once initial rep&ion is achieved. the role of rem& 
here for intravenous APSAC can be made with those of sion afwr APSAC appears b be low and may be attributed to 
intravenous streptokinase. Direct comparisons of intrave- APSAC’s long duratiw of action (36.371. However, it should 
nous streptokinase and APSAC are currently underway. be stressed that ir: our study many patients underwent early 
The drug label recommendation for dose and duration of 
introcoronary streptokinase is a b&s of 20,000 U then 2,0X1 
interventions. ascertaioment of potency status at I day was 
incomplete and an assessment of the true reocclusion rate 
Ulmin for 60 min. Although the investigators were aware could not be determined. 
that higher dose regimens (i.e., 4,ooO Ulmin) have also been Infarct size by eozymolic indexes ws similarfor rhc nw 
used in practice (26.28). these higher doses cwstitute “ex- frealment groups. The times to serum etzyme peaks and 
perimental therapy” in the FDA’s view and were unaccept- peak values were also consistent with those observed after 
able. Although a higher dose of strept-Goose might have repetfusion therapy in previous studies (10.11,13,49). AI- 
been slightly more effective, a clear dose-related response though left ventricular ftmctional changes after therapy are 
has not been established. Kennedy et al. (26) gave 4,000 not given in this report, such measurements are a relatively 
U/odn over I h in a controlled study and achieved 68% insensitive indicator of perfusion status and did oat show 
rewfuGon: we @we 2,ooO U/mitt and achieved 6+% net differences between the&es in the TIM1 studv desoite 
repwfusion W?X “anytime” roperfusion). Success rates 
Z-65 to 70% in wme other studiis (10) may be explained in 
part by inclusion of patients with subtotal occltion and use 
of less stringent determinations of repelfusion. 
Timbzg of Ihe clinical comparison end poim for imrxo. 
ronary streptokinase coincides with the end of the recom. 
twofold differences in rep&fusion rates (53). Mo&dity den- 
elits appear to be more sensitively predicted by reprfusiw 
status than by changes in ejection fraction afterthmmbolytic 
therapy (26,W). 
APSAC caused (1 made-rare decrease in blood pressure 
(median 10 mm Ha) sswciated with its rati administration 
mended infusion time and follows precedent from prior (over 2 to 4 min). 1; contrast, greater aver&e d creases have 
intracorotwy thromholysis trials (26.28). repafusion kinet- been reported with slower iufusions of esuivalmtt doses of 
its of intracomttary therapy (Fig. I) and clinical practice 
consensus, which favored additional maneuvers atIer I h for 
failed intracoronory therapy. It should be stressed that the 
study was designed to evaluate two diPrent thmmbolytic 
approaches (an experimental intraveoous regimen and a 
standard. approved iutracoronary regimen) and oat to com- 
tare the two dmas directlv. 
intravenous stmokinase. Lew et al. (54) observed a de- 
crease in systolic btood pressure of35 nun Hg at an average 
of I5 min during infusion of 750,wO U streptokinase over 30 
min. 
In rhe dost used in rhe pre~enr s&y (30 (I), APSAC 
caused subaanrial .r?brinogenolysis. The semiselectivity of 
fihtinolvtic effwt for clot rewrted earlier for APSAC ao- 
COIII~~WIZWI r;ith p&us trials of APSAC. In early, pears to be limited to doses dfsl0 U (36,373. However, the 
largely European experience. APSAC was given to patieatls bleeding risk after 30 U of APSAC appears acceptable and 
with acute myocardial infarction according to varying and similar to that for comparable dwes of streptokinase (7,473. 
often uncontrolled study designs with generally favorable Of the bleeding events (2?+% ineideoce rate). 53% were 
located al rhe site of catheter insertion and should be 
avoided in clinical practice if early angiography is PII 
pafommi. Significantly. no intracranial hemorrhage was 
observed. In comparison. in the invasive TIM1 study 161. 
puncture she bleeding associated with introvenous strepto- 
kinare occurred in 47% of ualients and CasLrointestinal 
bleeding in IO%. Bleeding rat& for I-PA plui heparin were 
43% for uu”cLure site bleedine md 6% for nactrointcstinai 
bleeding ‘(6). T-PA may &pose a risk ‘of intracranial 
hemorrhage. especially in higher doses (55). 
Conclusions. The present study should encourage further 
development of APSAC for clinical use in early reperfusion 
therapy fur acute myocardial infarction. When given early, 
APSAC achieves resuhr similar to intracnronary srreploki- 
nase therapy and probably better results than intravenous 
streplokinase (l,.(6). Because APSAC is easier to administer 
than both intracomnary and intravenous streptokinase and 
only infrequently c&es intolerable hypotemion despite 
rapid injection. its use should facilitate early administration 
ofthr&bolylic therapy. Direct comparisons of APSAC and 
intravenous weptokinare and other agents (such as t-PA) 
will be of interest in the future. 
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